Comparing Letermovir and Valganciclovir for CMV Prevention After Heart Transplant
This study is comparing two medications, letermovir and valganciclovir, to see which is safer and more effective at preventing Cytomegalovirus (CMV) infection after a heart transplant. CMV is a common virus that can cause serious problems for transplant patients. Valganciclovir is the standard treatment, but letermovir might have fewer side effects like low white blood cell counts (leukopenia) and low neutrophil counts (neutropenia). This study wants to see if letermovir works as well as valganciclovir in heart transplant patients, as it has in other transplant types. You may be able to join if you are over 18, have recently had a heart transplant, and have not yet started CMV prevention medicine. The study is currently recruiting about 150 participants.
- Study design
- This is a multi-center study where participants will be randomly assigned to receive either letermovir or valganciclovir. It aims to enroll 150 participants.
- What's involved
- Participants will receive CMV prophylaxis for up to 6 months for moderate risk or up to 12 months for high risk. Those receiving letermovir will also take acyclovir for 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for leukopenia and neutropenia during the entire duration of CMV prophylaxis, which can be up to 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
At a glance
Conditions
NCT07079735
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Columbia University/NYP Milstein Hospital
New York, New Yorkstudy coordinator listed
Recruiting
NYP-Weill Cornell
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Occurrence of leukopeniaDuring the duration of CMV prophylaxis (6 months for moderate risk and 12 months for high risk from start of therapy)
Number of patients with leukopenia (white blood cell count \<3000 cells µL)
- Occurrence of neutropeniaDuring the duration of CMV prophylaxis (Up to 6 months for moderate risk and up to 12 months for high risk from start of therapy)
Number of patients with neutropenia (absolute neutrophil count \<1500 cells/µL)